Drug Trial Radar · NCT02988960
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
163
Actual
Start
Feb 22, 2017
Primary completion
Sep 2026
Study completion Sep 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Dec 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumors Cancer
Interventions
ABBV-927Drug
Intravenous
ABBV-927Drug
Intratumoral
ABBV-181Drug
Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181Time frame: Up to 8 weeks
- Time to Cmax (Tmax) of ABBV-927Time frame: Up to 12 weeks after participant's first dose
- Maximum observed serum concentration (Cmax) of ABBV-927Time frame: Up to 12 weeks after participant's first dose
- Terminal-Phase Elimination Rate Constant (β) of ABBV-927Time frame: Up to 12 weeks after participant's first dose
- Terminal half-life (t1/2) of ABBV-927Time frame: Up to 4 weeks after participant's first dose
- Area under the serum concentration-time curve (AUCt) of ABBV-927Time frame: Up to 12 weeks after participant's first dose
- Time to Cmax (Tmax) of ABBV-181Time frame: Up to 12 weeks after participant's first dose
- Maximum observed serum concentration (Cmax) of ABBV-181Time frame: Up to 12 weeks after participant's first dose
- Terminal-Phase Elimination Rate Constant (β) of ABBV-181Time frame: Up to 12 weeks after participant's first dose
- Terminal half-life (t1/2) of ABBV-181Time frame: Up to 4 weeks after participant's first dose
- Area under the serum concentration-time curve (AUCt) of ABBV-181Time frame: Up to 12 weeks after participant's first dose
- Number of Participants with Adverse EventsTime frame: Up to 30 days after and up to 24-month of treatment period
Locations
22 sites in 7 countries. Site status is shown where the registry gives one.
The Angeles Clinic and Researc /ID# 156324
Los Angeles, California
The University of Chicago Medical Center /ID# 155264
Chicago, Illinois
Massachusetts General Hospital /ID# 155267
Boston, Massachusetts
Carolina BioOncology Institute /ID# 155265
Huntersville, North Carolina
Tennessee Oncology-Nashville Centennial /ID# 158654
Nashville, Tennessee
University of Texas MD Anderson Cancer Center /ID# 155263
Houston, Texas
Virginia Cancer Specialists - Fairfax /ID# 155266
Fairfax, Virginia
Peninsula Oncology Centre /ID# 164372
Frankston, Victoria, Australia
Austin Health /ID# 171189
Heidelberg, Victoria, Australia
University Health Network_Princess Margaret Cancer Centre /ID# 200819
Toronto, Ontario, Canada
Institut Bergonie /ID# 162665
Bordeaux, Gironde, France
Duplicate_Institut Regional du Cancer /ID# 163609
Montpellier, Herault, France
Centre Leon Berard /ID# 162663
Lyon, Rhone, France
Institut Gustave Roussy /ID# 162666
Villejuif, Val-de-Marne, France
National Cancer Center Hospital East /ID# 216870
Kashiwa-shi, Chiba, Japan
National Cancer Center Hospital /ID# 217758
Chuo-ku, Tokyo, Japan
Yonsei University Health System Severance Hospital /ID# 166292
Seoul, South Korea
Seoul National University Hospital /ID# 166291
Seoul, Seoul Teugbyeolsi, South Korea
Hospital Universitario Fundacion Jimenez Diaz /ID# 200128
Madrid, Spain
Hospital Universitario HM Sanchinarro /ID# 200127
Madrid, Spain
Hospital Universitario y Politecnico La Fe /ID# 200975
Valencia, Spain
Hospital Universitario Puerta de Hierro - Majadahonda /ID# 200129
Majadahonda, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.